html5-img
1 / 46

Treatment of heart failure(CHF)

Treatment of heart failure(CHF). Done by: Fatimah Al- Shehri Pharm.D candidate . King abdulaziz university Supervised by : Dr.Sara Al- Khansa. Outline :. 1-Introduction : - Definition. -Types. -Causes. 2-Pathophysiology. 3-Diagnosis. - Signs and symptoms. -Classification of HF.

demi
Download Presentation

Treatment of heart failure(CHF)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Treatment of heart failure(CHF) Done by:Fatimah Al-ShehriPharm.D candidate .King abdulaziz university Supervised by :Dr.Sara Al-Khansa.

  2. Outline : 1-Introduction : -Definition. -Types. -Causes. 2-Pathophysiology. 3-Diagnosis. -Signs and symptoms. -Classification of HF. 4-Mangment of CHF. -Goals of therapy. -Non-pharmacological therapy. -Pharmacological therapy. -Summary of guidelines treatment.

  3. Heart failure : Abnormality of cardiac structure or function leading to failure of the heart to deliver oxygen at a rate commensurate with the requirements of the metabolizing tissues, despite normal filling pressures. Types of heart failure : According to function: 1-Systolic HF. 2-Diastolic HF.

  4. Pathophysiology: Left sided heart failure : Systolic failure(systolic dysfunction): The left ventricle loses its ability to contract normally. The heart can't pump with enough force to push enough blood into circulation.

  5. ABC of heart failure Pathophysiology G Jackson, C R Gibbs, M K Davies, G Y H Lip Pathophysiology:

  6. Signs and symptoms : -Edema of feet , ankles , abdomen and lungs . -Congested jugular veins. -Loss of appetite. -Shortness of breath. -Fatigue and weakness. -↓↓Alertness or concentration.

  7. CAUSES : 1-Coronary artery disease. 2- Cardiomyopathy. 3-Hypertension. 4-Thyroid disease 5-Valvular heart disease. 6-Cardiotoxins . 7-Myocarditis . 8-Idiopathic.

  8. Diagnosis: 1-Medical history. 2-Physical examinations. 3-Laboratory tests. E.g:(B-type Natriuretic Peptide(BNP). 4-Radilogical methods: -Chest X- rays&CTscan&MRI. -ECG. EF<40).)-ECHO.

  9. Hunt SA et al. J Am coffcardiot 2001:83:2101.13. Farrett MH et al.JAMA.2002:287:890-7. Hunt SA et al.j AM coff cardio 2001:38:2101-13 Farrell MH et al .JAMA 2002:287:890-7

  10. Management of CHF:

  11. Principles and goals of therapy: 1-Block the compensatory neurohormonal activation caused by decreased CO . 2-Prevent/minimize Na and water retention . 3-Eliminate or minimize symptoms of HF . 4-Slow the progression of cardiac dysfunction 5-Decrease mortality. 6-Prevent hospital admission. 7- Improve survival.

  12. Management of CHF: 1-Nonpharmacological . 2-Pharmacological: 1-Diuretics. 2-ACEI or ARBS. 3-Beta blockers. 4-Aldosterone antagonist. 5-Digoxin. 6-Vasodilators.

  13. 1-Nonpharmacological : Life style changes : 1-Decrease fluid intake (2/L MAXIMUM). 2-Decease sodium. 3-Decreae weight. 4-Moderate exercise.

  14. 2-Pharmacological : 1-Diuretics : Place of therapy :all patients with heart failure. Types of diuretics : A- loop diuretics :(Furosemide,Torsemide, Ethycranicacid,Bumetinde).

  15. Mechanism of action

  16. 1-Diuretics : -Hypokalemia,hyponatermia,hypomagnesemis, hypocalcemia, -Dehydration. ototoxicity. -Hyperuercemia,hyperglycemia, hyperlipidemia. -Conistipation,Dryness of the mouth. -Muscle weakness. -wieghtloss,Skinrashes,hypotension. . Side effects of loop diuretics :

  17. 1-Diuretics : Contraindications of loop diuretics: Hypersensitivity. Monitoring : - Monitor electrolyte ,(K,Na,Ca). - Uric acid ,glucose.

  18. 1-Diuretics : B-Thaiazide diuretics: e.g:Hydrochlorothiazide. Mechanism of action

  19. 1-Diuretics : Side effects of thiazide diuretics: -Hypokalemia,Hyponatremia -Increased uric acid and glucose. -Increased cholesterol . -Hypomagnesemia -Hypotension. -Photosensitivity. -Headaches, Allergy thiazide diuretics :ofContraindications - Allergy to (sulphur-containing medications). - Gout. - Hypotension. - Renal failure. - Lithium therapy. - Hypokalemia.

  20. Diuretics and recommended doses:

  21. 2-ACEI : Place in therapy : For all patients with heart failure . e.g:(Lisinopril,Prendopril,Captopril,Enalpril,) Mechanism of action : (-Blocks production (AgII

  22. 2-ACEI : Side effects: -Dry cough. - Protinuria. Allergy. - Decrease taste . - Neutropenia. - Hyperkalemia. - Angioedema. - Acute renal failure. -Pregnancy. -Hypotension. -Bilateral renal stenosis. Contraindications:

  23. 2-ACEI: Monitoring : 1-SCr,and K in 1–2 weeks after starting or increasing the dose. 2-Monitor BP and symptoms of hypotension (e.g., dizziness, light-headedness). 3-Use cautiously in those with a baseline K greater than 5.0 mEq/L.

  24. ACEI and recommended doses :

  25. 2-ARBs: e.g:(Losartan.Candesartan.Valsartan) Place in therapy :If the patient cannot tolerate the side effect that produced by ACEI (dry cough). Side effects: the same as ACEI but with less cough.

  26. ARBS and recommended doses:

  27. 3-Beta Blockers : BB use in heart faliure : -Bisoprolol. -Metoprolo. -Carvedilol. Place in therapy: Shouldbe used in all stable patients. Mechanism of action: - Blocks the effect of NE and other sympathetic NT on the heart and vascular system.

  28. 3-Beta blockers: SIDE EFFECTS : 1-Hypoglycemia. 2-Hypotension. 3-Bradycardia. 4-Depression. 5-Edema.

  29. 3-Beta blockers: Contraindications: 1-Uncontrolled heart failure. 2-Prinzmetal's angina. 3-Bradycardia. 4-Hypotension. 5-Certain problems: (sinus syndrome). Monitoring : -BP, HR, and symptoms of hypotension (monitor in 1–2 weeks). -IF hypotension alone is the problem, try reducing the dose of the ACE inhibitor first. - Increased edema/fluid retention (monitor in 1–2 weeks).

  30. BB and recommended doses :

  31. 4-Aldosterone antagonist: E.g: Spironolactone,Eplerenone. Place in therapy: 1-Should be considered in patients after an acute MI, with clinical HF signs and symptoms or history of (diabetes, and an LVEF less than 40%). 2- Class III and IV HF. 3-LV dysfunction immediately after MI.

  32. 4-Aldosterone antagonists : Mechanism of action: Blocks effects of aldosterone in the kidneys, heart, and vasculature: (a) ↓K and Mg loss: Decreases ventricular arrhythmias. (b) ↓Na retention; decreases fluid retention . (c) Eliminates catecholamine; decreases BP.

  33. 4-Aldosterone antagonists: Side effects : Hyperkalemia. Gynecomastia. Dry mouth. Muscle weakness. Confusion, nausea, vomiting. Eplerenone:alternative to spironolactone in painful gynecomastia.

  34. 4-Aldosterone antagonists : Contraindications: 1-SCr is greater than 2.5 mg/dL, 2-(CrCl) is < 30 mL/min, 3-K is >5.0 mEq/L. MONITORING : 1-K and SCr within 1 week of starting therapy . 2- Decrease dose by 50% or discontinue if K is greater than 5.5 mEq/L. Dosing: (1) Spironolactone 12.5–25 mg/day . (2) Eplerenone 25–50 mg/day .

  35. 5-Digoxin: Place in therapy: In patients with LVEF of ≤40%,who have signs or symptoms of HF while receiving standard therapies including ACEI or ARBs and β-blockers. DOSING: 0.125 mg/day

  36. 5-Digoxin: Mechanism of action: Inhibits Na-K ATPase: i. Decreases central sympathetic outflow by sensitizing cardiac baroreceptors ii. Decreases renal reabsorption of Na. iii. Minimal increase in COP. Side effects : GIT disturnances.Bradycardia. Ventricular arrythmia. confusion, hallucinations, unusual thoughts or behavior. Abdominal pain, headache. Visual busturbances .

  37. 5-Digoxen: CONTRAINDICATIONS: - hypersensitivity. - Ventricular fibrillation. - Pregnancy Monitoring : 1-Serum concentrations should be less than 1.0 ng/mL, in general, concentrations of 0.7–0.9 ng/mL are effective in HF. 2- Risk of toxicity increases in the presence of hypokalemia or hypomagnesemia, older age ,RF.

  38. 6-Hydralazine and isosorbidedinitrate : Place in therapy: In Patients unable to take an ACE I OR ARBS. Due to : severe renal insufficiency, hyperkalemia, or angioedema.

  39. 6-Hydralazine and isosorbidedinitrate: Mechanism of action A-Hydralazine: (a) Arterial vasodilator (reduces afterload). (b) Enhances effect of nitrates through antioxidant mechanisms B- Isosorbidedinitrate: (a) Stimulates nitric acid signaling in the endothelium (b) Effective in reducing preload .

  40. 6-Hydralazine and isosorbidedinitrate: Side effects : A-Hydralazine : - Hypersensitivity. - Systemic lupus erythremataus . - Hypotension . -Headache. - GIT upset. B-Isosorbidedinitrate : - Blurred vision ,dry mouth. - Nausea, vomiting, sweating, pale skin. - Headache, hypotension ,mild dizziness. - Weakness.

  41. 6-Hydralazine and isosorbidedinitrate(ISDN): Monitoring : 1- Hypotension. 2-Drug-induced lupus with hydralazine. Dosing : - Hydralazine(25–75 mg 3-4times/day). - Isosorbidedinitrate (10–40 mg 3times/ day).

  42. Benefits of each group : .

  43. Summary : Yancy, CW et al. 2013 ACCF/AHA Heart Failure Guideline

  44. References :

  45. Pharm.D candidate :Fatimah Al-Shehri.

More Related